anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To prevent the inclusion of air in a kneaded product, and to keep the feeding pressure of the kneaded product to the filling apparatus at a constant level, by attaching a temporary storage cylinder to a pipe connecting a pump with the filling apparatus, and storing the excessive discharge of the pump in the cylinder. CONSTITUTION:The kneaded product is transferred under pressure with a pump, and air is exhausted by opening the air valve 5. k-Filling apparatuses of the total m-apparatuses are operated, and the excessive kneaded material which cannot be treated with the filling apparatuses is stored in the storage cylinder 8 by pushing the free piston 9 rightward. When the piston 9 reaches the right end of the cylinder 8, the driving motor of the pump is stopped by the action of the magnetic proximity switch. The free piston 9 is pushed with the piston 20, and the kneaded product stored in the cylinder is extruded to the filling apparatus. When the piston 9 reaches the left end of the cylinder 8, the pump is started again by the action of the magnetic proximity switch 14, and the excessive product is stored in the storage cylinder 8. The above steps are repeated.
BACKGROUND: Bilateral adrenal hemorrhage is a rare but often a fatal cause of primary adrenal insufficiency that can result in adrenal crisis if not identified and managed appropriately.
CASE PRESENTATION: We present a case of a 27-year-old Caucasian female who was admitted to the hospital 17 days postpartum with pleuritic chest and flank pain, shortness of breath and nausea. Computed tomography imaging confirmed multiple thromboemboli including pulmonary emboli and noted bilateral bulky adrenal glands. She was managed for infection and pulmonary emboli; however, she complained of persistent headaches, nausea, and vomiting despite appropriate management. Radiology re-review found the computed tomography imaging was consistent with bilateral adrenal hemorrhage in hindsight. Subsequent endocrine evaluation with hypothalamic-pituitary-adrenal axis interrogation and adrenocorticotropic hormone (Synacthen) stimulation testing confirmed resultant primary adrenal insufficiency. She required urgent intravenous hydrocortisone and was subsequently discharged on oral adrenal replacement therapy and anticoagulation.
CONCLUSIONS: Delay in identification and treatment of adrenal insufficiency can lead to catastrophic outcomes. This case highlights the challenge of diagnosing bilateral adrenal hemorrhage and resultant adrenal insufficiency as patients may not present with the classic risk factors, signs, symptoms, and electrolyte derangements.
LncRNA plays key role in several biological processes, including transcriptional regulation, post transcriptional control and epigenetic regulation. However, research on the functional roles of lncRNAs in teleost species remains limited. Here, we discovered a lncRNA (BCO1-AS) with a critical role in antibacterial responses. Briefly, the full length of BCO1-AS was 2005 bp. Subsequently, BCO1-AS was distributed throughout the nucleus, where it may either trans- or cis-regulate the nearby genes. In addition, BCO1-AS was widely expressed in all the examined tissues with the highest expression level in intestine, while the lowest expression level was detected in muscle. Moreover, following Vibrio anguillarum challenge, BCO1-AS was significantly down-regulated in intestine, and up-regulated in gill and skin. In CHIRP experiment, BCO1-AS could effectively enrich RNA and might interact with several immune-related genes. Furthermore, we found that LPS could induce the expression of BCO1-AS. Finally, BCO1-AS could positively regulate caspase-1 at the mRNA and protein level. The BCO1-AS was speculated to inhibit the synthesis of inflammatory components. In summary, these results showed the roles of BCO1-AS in the regulation of inflammatory in turbot, which provided valuable information for further understanding the immune regulation network of lncRNA in teleost fish.
A fibrin wound dressing is made by mixing quantities of fibrinogen solution and thrombin solution with air. The resulting foam is very light weight, and with the proper attention to the amount of thrombin, is also sufficiently viscous to rest on a vertical surface without dripping. The wound dressing may also be formulated for its ability to continue migration of healing substances, such as PDGF, from the dressing to the wound site. Thrombin substitutes, such as other clotting proteins, may be used instead of thrombin. The resulting foam may also be lyophilized or ground and lyophilized for later reconstitution. A therapeutic drug or other additive may also be added to the wound dressing.
Ketorolac tromethamine is a member of the pyrrolo-pyrrole group of non-steroidal anti-inflammatory drugs (NSAIDs). The chemical name for ketorolac tromethamine is (±)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol, and the structural formula is:

Ketorolac tromethamine is a racemic mixture of [-]S and [+]R ketorolac tromethamine. Ketorolac tromethamine may exist in three crystal forms. All forms are equally soluble in water. Ketorolac tromethamine has a pKa of 3.5 and an n-octanol/water partition coefficient of 0.26. The molecular weight of ketorolac tromethamine is 376.41.

Each tablet for oral administration contains 10 mg ketorolac tromethamine, USP. In addition, each tablet contains the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium lauryl sulfate, titanium dioxide and triacetin.
Osteoarthritis is the most common joint disorder. However, there are no disease-modifying drugs approved for OA treatment. CDC2-like kinase 2 (CLK2) could modulate Wnt signaling via alternative splicing of Wnt target genes and further affect bone differentiation, chondrocyte function, and inflammation, making CLK2 an attractive target for OA therapy. In this study, we designed and synthesized a series of highly potent CLK2 inhibitors based on Indazole 1. Among them, compound LQ23 showed more elevated inhibitory activity against CLK2 than the lead compound (IC50, 1.4 nM) with high CLK2/CLK3 selectivity (>70-fold). Furthermore, LQ23 showed outstanding antiosteoarthritis effects in vitro and in vivo, with the roles specific in decreased inflammatory cytokines, downregulated cartilage degradative enzymes, and increased joint cartilage via suppressing CLK2/Wnt signaling pathway. Overall, these data support LQ23 as a potential candidate for intra-articular knee OA therapy, leveraging its unique mechanism of action for targeted treatment.
Objectives: To prospectively evaluate the effects of early weight status (childhood and adolescence) and changes in obesity status on human capital in adulthood. Methods: We employed data from the 1970 Birth Cohort Study in the United Kingdom. Data on height and weight during childhood and adolescence, human capital variables in adulthood were collected from 2,444 participants. Human capital includes cognitive ability, non-cognitive skill, educational attainment and health status. Data were analyzed through linear regression and logistic regression models. Results: Our results showed that obesity during adolescence was negatively associated with cognitive ability (β = -0.83, p < 0.01), educational attainment (β = -0.49, p < 0.01), and some health outcomes; and that underweight in childhood also adversely affected educational attainment in females (β = -0.66, p < 0.05). In terms of changes in obesity status, becoming obese in adolescence negatively affected cognitive ability (β = -1.18, p < 0.01), educational attainment (β = -0.62, p < 0.05) and some health outcomes, remaining obese was associated with all adverse health outcomes. Conclusion: Our results suggest that obesity during adolescence negatively affects a range of human capital outcomes in adulthood, and adolescence is a critical period during which early obesity affects adult human capital.
The invention belongs to the technical field of medical product application, and discloses a cerebrovascular development malformation caused by DDX24 deficiency or dysfunction and application thereof. In the early stage of vascular development, DDX24 was highly expressed in vascular endothelial cells. Loss of DDX24 inhibited cerebrovascular development in zebrafish and mice. Mechanism researches show that the DDX24 deletion can down regulate the expression of GPR124 in brain vascular endothelial cells, thereby inhibiting Wnt/beta-catenin signaling. When the Wnt pathway is activated during cerebrovascular development, vascular abnormalities caused by the loss of DDX24 can be recapitulated. Our findings show that DDX24 is a regulator of early vascular development and is essential for the development of the cerebrovascular system.
An emulsifier for a water in oil emulsion comprises a monofatty acid ester of an unsaturated fatty acid with a symmetrical or asymmetrical disubstituted hydroxalkylurea or hydroxyalkylthiourea.  Two general formulae for the esters are <FORM:1038015/A5-A6/1> where X, Y may be the same or different and are each one of the following <FORM:1038015/A5-A6/2> where n > 1, m \sF 1 and R is an alkyl radical having at least 10 carbon atoms which is preferably unsaturated and may contain hydroxyl groups.  The urea oxygen may be replaced by sulphur.  The emulsifier may be prepared by thermal or catalytic esterification of urea derivatives, by ester interchange from fatty acid esters by esterification via a corresponding acid chloride or by preparing an amine ester hydrochloride and converting the amino group to urea using cyanates.  16 examples of emulsifier are given.  The emulsifier is mixed with paraffin or petroleum jelly which is then emulsified with water, the product being used in cosmetics.ALSO:An emulsifier for a water in oil emulsion comprises a monofatty acid ester of an unsaturated fatty acid with a symmetrical or asymmetrical disubstituted hydroxyalkylurea or hydroxyalkylthiourea.  Two general formulae for the esters are:  <FORM:1038015/B1-B2/1> where X, Y may be the same or different and are each one of the following: <FORM:1038015/B1-B2/2> where n > 1, m   1 and R is an alkyl radical having at least 10 carbon atoms which is preferably unsaturated and may contain hydroxyl groups.  The urea oxygen may be replaced by sulphur.  The emulsifier may be prepared by thermal or catalytic esterification of urea derivatives, by ester interchange from fatty acid esters, by esterification via a corresponding acid chloride or by preparing an amine ester hydrochloride and converting the amino group to urea using cyanates, 16 examples of emulsifier are given. The emulsifier is mixed with paraffin or petroleum jelly which is then emulsified with water, the product being used in cosmetics, pest destruction or textiles industry.
Standard midwifery practices and labor follow-up were applied to women who met the inclusion criteria in the hospital (during the delivery room) (n: 187), agreed to participate in the study, and were in the control group. Neonatal routine care procedures (vaccine, footprint, eye drop application, etc.) of the postpartum hospital were performed. Then, after 2 hours postpartum, mothers were asked to fill in a personal questionnaire and a traumatic birth scale. The maternal attachment scale was completed 1 month after birth by telephone interview.
Cyclosporine gave no evidence of mutagenic or teratogenic effects in appropriate test systems. Only at dose levels toxic to dams, were adverse effects seen in reproduction studies in rats (see Pregnancy). 

Carcinogenicity studies were carried out in male and female rats and mice. In the 78-week mouse study, at doses of 1, 4, and 16 mg/kg/day, evidence of a statistically significant trend was found for lymphocytic lymphomas in females, and the incidence of hepatocellular carcinomas in mid-dose males significantly exceeded the control value. In the 24-month rat study, conducted at 0.5, 2, and 8 mg/kg/day, pancreatic islet cell adenomas significantly exceeded the control rate in the low-dose level. The hepatocellular carcinomas and pancreatic islet cell adenomas were not dose related.

Cyclosporine has not been found mutagenic/genotoxic in the Ames test, the V79-HGPRT Test, the micronucleus test in mice and Chinese hamsters, the chromosome-aberration tests in Chinese hamster bone marrow, the mouse dominant lethal assay, and the DNA-repair test in sperm from treated mice. A recent study analyzing sister chromatid exchange (SCE) induction by cyclosporine using human lymphocytes in vitro gave indication of a positive effect (i.e., induction of SCE), at high concentrations in this system. 

In a fertility study in rats, increased perinatal mortality and impaired postnatal development of F1 pups were observed at 15 mg/kg/day (0.2 times the MRHD based on BSA). No adverse effects on fertility and reproduction were observed up to 5 mg/kg/day (0.06 times the MRHD based on BSA) in male and female rats.

An increased incidence of malignancy is a recognized complication of immunosuppression in recipients of organ transplants. The most common forms of neoplasms are non-Hodgkin’s lymphoma and carcinomas of the skin. The risk of malignancies in cyclosporine recipients is higher than in the normal, healthy population, but similar to that in patients receiving other immunosuppressive therapies. It has been reported that reduction or discontinuance of immunosuppression may cause the lesions to regress.
Sympathetic stimulation is necessary in supporting circulatory function in congestive heart failure, and beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure. Continued depression of the myocardium with beta blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of impending cardiac failure, esmolol hydrochloride should be withdrawn. Although withdrawal may be sufficient because of the short elimination half-life of esmolol hydrochloride, specific treatment may also be considered (see OVERDOSAGE). The use of esmolol hydrochloride for control of ventricular response in patients with supraventricular arrhythmias should be undertaken with caution when the patient is compromised hemodynamically or is taking other drugs that decrease any or all of the following: peripheral resistance, myocardial filling, myocardial contractility, or electrical impulse propagation in the myocardium. Despite the rapid onset and offset of the effects of esmolol hydrochloride, several cases of death have been reported in complex clinical states where esmolol hydrochloride was presumably being used to control ventricular rate.
A condom with a vasodilator delivery system is provided for producing and maintaining the erection of a male penis during intercourse.  The vasodilator is contained in a transdermal patch. The patch may be used with or without a condom, and may be used inside of a condom. Where used inside of a condom, the patch is adhered during manufacture to the condom inside wall (10). The transdermal patch comprises a thin, smooth-edged layered structure for dispensing a suitable vasodilator to the penis skin surface (13). Where used inside a condom, the transdermal patch may remain attached to the condom inner wall during sexual intercourse, or may be made releasable from the condom wall so that it adheres only to the skin of the penis. In each embodiment of the patch, the vasodilator is applied to the skin of the user and is seated against unwanted contraindicated leakage and contact with the internal tissue of a sex partner.
During a single blind, run-in period, participants received placebo. Then at randomization (double blind treatment period), participants started with 40 mg Valsartan twice daily (bid) for 1 - 2 weeks, then were uptitrated to 80 mg bid for 1 -2 weeks, and thereafter, uptitrated to 160 mg bid.
The idea behind the use of local anesthetic agents in the peri-operative period is not only related to its ability to block peripheral nociceptor transmission after tissue damage but also in preventing sensitization of the central nervous system. Levobupivacaine is new, long-acting bupivacaine, amide-type local anesthetic and is thought to be less cardio and neurotoxic. However, few studies showed that local infiltration of levobupivacaine reduces the intensity of postoperative pain. Dexmedetomidine is a highly selective α2-adrenoceptor agonist recently introduced to anesthesia practice producing dose-dependent sedation, anxiolysis, and analgesia (involving spinal and supraspinal sites), without respiratory depression. Dexmedetomidine is being used off-label as an adjunctive agent in pediatric patients for sedation and analgesia; in the critical care unit, during non-invasive ( Magnetic resonance imaging) and invasive procedures ( cardiac catheterization and endoscopy). It may also decrease opioid usage and anesthesia requirements as seen from adult data prevent emergence delirium and postanesthesia shivering.
BACKGROUND: The risk of morbidity and mortality in the group of people qualified for kidney transplantation is high. Although currently, the qualification for kidney transplantation is very extensive and detailed, the final examination and assessment at the transplant center is crucial for the success of the transplantation.
CASE REPORT: A 50-year-old woman with end-stage kidney disease was admitted to the Department of General, Vascular, and Transplant Surgery on July 21, 2023, for kidney transplantation. A month earlier, she had undergone surgery to create an arteriovenous fistula on the left forearm. The regional anesthesia was performed. Apart from temporary pain and cough, the postoperative course was uncomplicated. Upon admission to the Department, the patient was in good general condition, and only a dry cough was noted during the physical examination. Chest X-ray revealed pneumothorax on the left side with partial lung atelectasis. The patient was temporarily disqualified from kidney transplantation and the pneumothorax was cured. She is currently on the active list waiting for a kidney transplant.
CONCLUSIONS: The analysis of the above case emphasizes the importance of a physical examination and final qualification at the transplant center. Detailed examination and evaluation at the above center can improve patients' quality of life and survival.
This group will undergo a 9-month dietary intervention targeting consumption of all daily caloric intake within an 8-hour window of time, with no restrictions on caloric intake. During the first 6 months, participants will meet in-person once per month individually and three times per month in a group setting with a dietitian and/or behavioral coach. During the remaining 3 months of intervention, there will be one group and one individual meeting each month. Participants in TRE will be asked to log into the study-specific Companion App each day to document the beginning and end of their feeding cycles with timing of meals/snacks consumed. As in the CR arms, participants will use wrist-worn Fitbit step monitors to track their physical activity and receive feedback via the app, with a goal to promote movement across the day, increasing daily step count. Continuous glucose monitoring will be used at intervals to document glucose levels over a 7-10-day period.
For more than 4 decades, pediatricians have sought the best practices for effectively managing well-appearing young febrile infants. In 2021, the American Academy of Pediatrics released a clinical practice guideline for the management of well-appearing febrile infants aged 8 to 60 days. The guideline incorporates advancements in testing, such as biomarkers and diagnostic testing in the setting of changing epidemiology, to help risk stratify infants in the newly formed group age 22 to 28 days as well as the group age 29 to 60 days. The new guideline uses inflammatory markers (procalcitonin, C-reactive protein, absolute neutrophil count, and a temperature >38.4°C) to identify infants at low risk for invasive bacterial infection who can potentially avoid the invasive procedures of lumbar puncture, hospitalization, and broad-spectrum antimicrobials. Because of continued ambiguity, incorporating shared decision-making with families in the care of these infants will be important, as will ongoing clinical research to better inform future practice. [Pediatr Ann. 2024;53(6):e202-e207.].
This was an observation study that included a control group. We enrolled 20 patients with knee OA, as well as 10 healthy individuals. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Kellgren-Lawrence X-ray grading were employed to determine disease severity. All the study participants received elastography assessment, including strain and shear wave elastography in the knee extension and flexion position. The strain elastography contained color mapping that enabled the calculation of the relative texture and strain ratio. The shear wave elastography revealed the qualitative velocity, which was measured 3 times. Each patients with knee OA received elastography examination twice: once before hyaluronic acid injection and once 1 month after the injection.
PURPOSE: A compound having excellent activity to melanocortin is provided to apply to functional agonist of the melanocortin receptor and to prevent and treat obesity, electrile dysfunction, diabetes, or inflammation. CONSTITUTION: A composition having excellent activity to melanocortin receptor is denoted by chemical formula 1. The compound of chemical formula 1 is obtained by amide-coupling a compound of chemical formula 2 with a compound of chemical formula 3. A method for preparing the compound of chemical formula 1 comprises: a step of deprotecting a compound of chemical formula 1' or 2'; a step of performing reductive amine reaction of oxo substituent with C1-C2 alkyl, C3-C7 cycloalkyl, or heterocycle; or a step of performing coupling reaction with arylhalide or hetero arylhalide. The composition contains pharmaceutically acceptable carrier, and the compound of chemical formula 1, pharmaceutically acceptable salt, or isomer. The composition is used for treating obesity, electrile dysfunction, diabetes, or inflammation.